Market Overview

MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE

Related IMUC
ImmunoCellular Announces Update on ICT-107
ImmunoCellular Therapeutics Letter to Shareholders Highlights Progress on Advancing ICT-107 to Phase 3 Registrational Trial

MLV & Co reiterates its Buy rating with a $4.50 price target on ImmunoCellular Therapeutics (NYSE: IMUC) as the company gets its listing on the NYSE starting next week.

MLV & Co comments, "We view this move as an affirmation of the company's commitment to growing their pipeline, and providing opportunities for their investors. The move also signals to us that the company is confident in its business model moving forward. ImmunoCellular operates on a cost-efficiency basis of collaboration and outsourcing of product development and clinical trial management."

IMUC closed at $2.82 on Thursday.

Latest Ratings for IMUC

Dec 2013McNicoll Lewis VlakDowngradesBuyHold
Dec 2013Roth CapitalDowngradesBuyNeutral
Mar 2013McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for IMUC
View the Latest Analyst Ratings

Posted-In: MLV & CoAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (IMUC)

View Comments and Join the Discussion!

Get Benzinga's Newsletters